APLS Live signals | Maximize Profits with Getagraph.com

BUY 155 min ago

@ $39.61

Issued: 29 May 2024 @ 09:30

Return: 1.93%

Previous signal: May 28 - 11:09

Previous signal: Sell

Return: -1.93 %

Live Chart Being Loaded With Signals

Commentary (29 May 2024 @ 12:05):

Stats
Today's Volume	483 579
Average Volume	1.43M
Market Cap	4.90B
EPS	$0 ( 2024-05-07 )
Next earnings date	( $-0.330 ) 2024-07-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.77
ATR14	$1.372 (3.40%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-20	Deschatelets Pascal	Buy	24 500	Common Stock
2024-05-20	Deschatelets Pascal	Sell	24 500	Stock Option (Right to Buy)
2024-05-08	Deschatelets Pascal	Buy	78 907	Common Stock
2024-05-08	Deschatelets Pascal	Sell	56 335	Common Stock
2024-05-08	Deschatelets Pascal	Sell	22 472	Common Stock

INSIDER POWER
-11.61
Last 100 transactions
Buy: 926 414 \| Sell: 1 130 718

Volume Correlation

Long: -0.11 (neutral)

Short: -0.05 (neutral)

Signal:(44) Neutral

Apellis Pharmaceuticals Correlation

10 Most Positive Correlations
OZEM	1
DLHC	0.954
MPAA	0.943
APDN	0.942
MBIO	0.935
JACK	0.933
ALGT	0.933
SHLS	0.932
TOI	0.931
APVO	0.929

10 Most Negative Correlations
VCTR	-0.945
BNTC	-0.941
AEYE	-0.94
NKTR	-0.939
SMTC	-0.938
KALU	-0.935
FRLA	-0.931
RVMD	-0.929
CGBD	-0.928
GGAL	-0.928

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Apellis Pharmaceuticals Correlation - Currency/Commodity

0.15
( neutral )

0.22
( neutral )

0.00
( neutral )

-0.40
( neutral )

-0.31
( neutral )

0.04
( neutral )

Apellis Pharmaceuticals Financials

Annual	2023
Revenue:	$396.59M
Gross Profit:	$336.38M (84.82 %)
EPS:	$-4.45

FY	2023
Revenue:	$396.59M
Gross Profit:	$336.38M (84.82 %)
EPS:	$-4.45

FY	2022
Revenue:	$75.42M
Gross Profit:	$69.79M (92.53 %)
EPS:	$-6.15

FY	2021
Revenue:	$66.56M
Gross Profit:	$61.36M (92.19 %)
EPS:	$-8.84

Financial Reports:

No articles found.

Apellis Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.